Nautilus Biotechnology (NAUT) Competitors

$2.02 -0.15 (-6.71%)

As of 10:35 AM Eastern

NAUT vs. CYRX, PACB, MLAB, CTKB, and OABI

Should you buy Nautilus Biotechnology stock or one of its competitors? Nautilus Biotechnology's main competitors and comparable companies include CryoPort (CYRX), Pacific Biosciences of California (PACB), Mesa Laboratories (MLAB), Cytek Biosciences (CTKB), and OmniAb (OABI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Nautilus Biotechnology compare to CryoPort?

Nautilus Biotechnology (NASDAQ:NAUT) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, CryoPort had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for CryoPort and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.91 beat CryoPort's score of 0.79 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Positive
CryoPort	Positive

Nautilus Biotechnology has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

Nautilus Biotechnology has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. CryoPort's return on equity of -7.20% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
CryoPort	-20.05%	-7.20%	-4.30%

Nautilus Biotechnology presently has a consensus price target of $3.83, suggesting a potential upside of 77.47%. CryoPort has a consensus price target of $19.33, suggesting a potential upside of 16.19%. Given Nautilus Biotechnology's higher probable upside, analysts clearly believe Nautilus Biotechnology is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 9.5% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

CryoPort has higher revenue and earnings than Nautilus Biotechnology. CryoPort is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
CryoPort	$176.18M	4.78	$78.30M	-$0.90	N/A

Summary

CryoPort beats Nautilus Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Pacific Biosciences of California (NASDAQ:PACB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Nautilus Biotechnology has lower revenue, but higher earnings than Pacific Biosciences of California. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	3.87	-$546.38M	-$0.43	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Pacific Biosciences of California currently has a consensus price target of $1.71, indicating a potential downside of 13.94%. Nautilus Biotechnology has a consensus price target of $3.83, indicating a potential upside of 77.47%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Pacific Biosciences of California had 9 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 10 mentions for Pacific Biosciences of California and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.91 beat Pacific Biosciences of California's score of 0.78 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Pacific Biosciences of California	Positive
Nautilus Biotechnology	Positive

Pacific Biosciences of California has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Nautilus Biotechnology has a net margin of 0.00% compared to Pacific Biosciences of California's net margin of -82.49%. Nautilus Biotechnology's return on equity of -37.58% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

50.7% of Nautilus Biotechnology shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nautilus Biotechnology beats Pacific Biosciences of California on 10 of the 16 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Mesa Laboratories?

Nautilus Biotechnology (NASDAQ:NAUT) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Mesa Laboratories has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Mesa Laboratories	$249.73M	2.83	$6.71M	$0.84	150.19

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 2.8% of Mesa Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Mesa Laboratories had 6 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 7 mentions for Mesa Laboratories and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.91 beat Mesa Laboratories' score of 0.51 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Positive
Mesa Laboratories	Positive

Nautilus Biotechnology has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Mesa Laboratories has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Mesa Laboratories has a net margin of 1.92% compared to Nautilus Biotechnology's net margin of 0.00%. Mesa Laboratories' return on equity of 22.72% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Mesa Laboratories	1.92%	22.72%	9.82%

Nautilus Biotechnology currently has a consensus target price of $3.83, indicating a potential upside of 77.47%. Mesa Laboratories has a consensus target price of $110.00, indicating a potential downside of 12.81%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Mesa Laboratories beats Nautilus Biotechnology on 10 of the 16 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Cytek Biosciences had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Cytek Biosciences and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.91 beat Cytek Biosciences' score of 0.86 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytek Biosciences	Positive
Nautilus Biotechnology	Positive

Cytek Biosciences currently has a consensus target price of $5.56, suggesting a potential upside of 3.20%. Nautilus Biotechnology has a consensus target price of $3.83, suggesting a potential upside of 77.47%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Cytek Biosciences has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Nautilus Biotechnology has a net margin of 0.00% compared to Cytek Biosciences' net margin of -38.98%. Cytek Biosciences' return on equity of -12.40% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Nautilus Biotechnology has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.48	-$66.54M	-$0.62	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Summary

Nautilus Biotechnology beats Cytek Biosciences on 9 of the 16 factors compared between the two stocks.

How does Nautilus Biotechnology compare to OmniAb?

Nautilus Biotechnology (NASDAQ:NAUT) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Nautilus Biotechnology has a net margin of 0.00% compared to OmniAb's net margin of -115.12%. OmniAb's return on equity of -16.59% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
OmniAb	-115.12%	-16.59%	-14.82%

Nautilus Biotechnology has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, OmniAb has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Nautilus Biotechnology currently has a consensus price target of $3.83, suggesting a potential upside of 77.47%. OmniAb has a consensus price target of $11.50, suggesting a potential upside of 152.75%. Given OmniAb's higher possible upside, analysts clearly believe OmniAb is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
OmniAb	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nautilus Biotechnology has higher earnings, but lower revenue than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
OmniAb	$18.67M	35.28	-$64.78M	-$0.36	N/A

In the previous week, OmniAb had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for OmniAb and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.91 beat OmniAb's score of 0.78 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Positive
OmniAb	Positive

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nautilus Biotechnology and OmniAb tied by winning 8 of the 16 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$256.41M	$10.73B	$7.43B	$12.75B
Dividend Yield	N/A	1.45%	2.52%	19.59%
P/E Ratio	-4.48	31.94	274.89	25.07
Price / Sales	N/A	104.67	568.47	74.22
Price / Cash	N/A	27.31	76.68	52.75
Price / Book	1.63	5.99	10.37	5.90
Net Income	-$59M	$56.67B	$3.49B	$380.43M
7 Day Performance	10.71%	-2.31%	-3.10%	-4.14%
1 Month Performance	126.13%	2.72%	-7.39%	-6.70%
1 Year Performance	83.18%	20.15%	1.29%	-6.43%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	2.8559 of 5 stars	$2.02 -6.7%	$3.83 +90.2%	+129.7%	$256.41M	N/A	N/A	130	News Coverage Gap Down
CYRX CryoPort	3.4006 of 5 stars	$17.80 -1.9%	$18.38 +3.2%	+78.5%	$918.78M	$176.18M	N/A	738	Analyst Forecast
PACB Pacific Biosciences of California	1.2221 of 5 stars	$2.70 -5.9%	$1.71 -36.6%	+25.2%	$892.08M	$160.01M	N/A	485	Analyst Upgrade Gap Down High Trading Volume
MLAB Mesa Laboratories	1.4909 of 5 stars	$136.06 -4.3%	$110.00 -19.2%	+76.5%	$795.90M	$249.13M	161.98	717	Dividend Announcement
CTKB Cytek Biosciences	1.6605 of 5 stars	$5.38 -11.7%	$5.56 +3.4%	+34.4%	$791.60M	$201.49M	N/A	702

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. CYRX, PACB, MLAB, CTKB, and OABI

How does Nautilus Biotechnology compare to CryoPort?

Summary

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Summary

How does Nautilus Biotechnology compare to Mesa Laboratories?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Summary

How does Nautilus Biotechnology compare to OmniAb?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. CYRX, PACB, MLAB, CTKB, and OABI

How does Nautilus Biotechnology compare to CryoPort?

Does the media refer more to NAUT or CYRX?

Which has more volatility and risk, NAUT or CYRX?

Is NAUT or CYRX more profitable?

Do analysts rate NAUT or CYRX?

Do insiders and institutionals have more ownership in NAUT or CYRX?

Which has stronger earnings & valuation, NAUT or CYRX?

Summary

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Which has higher earnings and valuation, PACB or NAUT?

Do analysts prefer PACB or NAUT?

Does the media prefer PACB or NAUT?

Which has more volatility and risk, PACB or NAUT?

Is PACB or NAUT more profitable?

Do insiders & institutionals believe in PACB or NAUT?

Summary

How does Nautilus Biotechnology compare to Mesa Laboratories?

Which has stronger earnings and valuation, NAUT or MLAB?

Do institutionals and insiders believe in NAUT or MLAB?

Does the media favor NAUT or MLAB?

Which has more risk and volatility, NAUT or MLAB?

Is NAUT or MLAB more profitable?

Do analysts recommend NAUT or MLAB?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Does the media prefer CTKB or NAUT?

Do analysts recommend CTKB or NAUT?

Which has more volatility and risk, CTKB or NAUT?

Do institutionals & insiders have more ownership in CTKB or NAUT?

Is CTKB or NAUT more profitable?

Which has preferable earnings & valuation, CTKB or NAUT?

Summary

How does Nautilus Biotechnology compare to OmniAb?

Is NAUT or OABI more profitable?

Which has more risk and volatility, NAUT or OABI?

Do analysts rate NAUT or OABI?

Which has better valuation and earnings, NAUT or OABI?

Does the media favor NAUT or OABI?

Do insiders & institutionals hold more shares of NAUT or OABI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools